05.11.26 -- The East Is Ready: A New Axis Of Pharmaceutical Innovation

To ensure that your adeno-associated virus (AAV) therapy reaches patients as soon as possible, begin your relationship with an experienced AAV manufacturer early in the development journey.

Explore 2026 policy trends across drug‑pricing actions, affordability pressures, value‑driven evaluation, shifts in global innovation, and new AI regulatory applications.

Industry leaders in North Carolina discuss how automation, AI, workforce training, and collaboration are shaping the future of manufacturing, highlighting a shared focus on sustainable growth.

Surging demand for highly potent drugs is driven by targeted therapies, stricter containment standards, increased outsourcing, and the need for specialized, compliant manufacturing.

The FDA is rethinking CMC oversight for cell and gene therapies, prioritizing science‑based justification over rigid validation models. Learn how this lifecycle‑focused approach could reduce burden.

Integrate a strategic intellectual property approach early in drug development to streamline research, uncover opportunities, and maximize the return on your investment.

How do biopharma companies solve the common challenge of increasing output while decreasing headcount? Explore three options: temporary staffing, outsourcing, and insourcing.

An optimized IVT platform delivers scalable, high-yield, cost-efficient mRNA production through data-driven optimization and enzyme innovation that address key manufacturing challenges.